Mxe.jpg

Methoxetamine (3-MeO-2-Oxo-PCE) is a near chemical analogue of Ketamine and PCP. It was first publicly reported in 2010. Some say it's similar to Ketamine or high doses of DXM. Methoxetamine differs from many dissociatives such as ketamine and phencyclidine that were developed as pharmaceuticals in that it was designed specifically for grey market distribution, making it a rare instance of a true designer drug. It has been shown to act as an NMDAN-methyl-D-aspartate receptor. NMDA antagonists are often dissociatives. receptor antagonistA substance that interferes with or inhibits the physiological action of another. and unlike ketamine also acts as SerotoninA monoamine neurotransmitter, biochemically derived from tryptophan, that is primarily found in the gastrointestinal (GI) tract, platelets, and central nervous system (CNS) of humans and animals. It is a well-known contributor to feelings of well-being. Reuptake Inhibitor (SRISerotonin Reuptake Inhibitor). The N-Ethyl group on this compound increases potency.

Dosage

Oral
Threshold 5-20mg
Low 10-30mg
Common 40-60mg
Strong 50-100mg+
Insufflated
Threshold 5-15mg
Low 15-30mg
Common 30-50mg
Strong 50-75mg
Hole 75-100mg+
Sublingual
Threshold 5-10mg
Low 10-20mg
Common 40-60mg
Strong 60-75mg
Hole 75-100mg+

Duration

Oral
Onset 30-60 minutes
Total 3-6 hours
After-effects 2-48 hours (dose-dependent)
Insufflated
Onset 5-40 minutes
Total 3-6 hours
After-effects 2-48 hours (dose-dependent)
Sublingual
Onset 15-45 minutes
Total 3-6 hours
After-effects 2-48 hours (dose-dependent)

Effects

Positive

  • Euphoria, mood lift
  • Sense of calm and serenity
  • Vivid recall of past memories and dreams
  • Closed- and open-eye visuals (common)
  • Out-of-body experience (less intense then ketamine)

Neutral

  • Distortion or loss of sensory perceptions (common)
  • Dissociation of mind from body
  • Sweating
  • Analgesia, numbness
  • Significant change in perception of time
  • Increase in heart rate
  • Confusion, disorientation

Negative

  • Risk of psychological dependency
  • Nasal discomfort upon insufflation
  • Blacking out and forgetting one has taken a drug
  • Discomfort, pain or numbness at injection site (with IM)
  • Severe confusion, disorganised thinking
  • Vertigo, spinning sensation (risk of injury)
  • Nausea, vomiting
  • Susceptibility to accidents (from uncoordination and change in perception of body and time)
  • Severe dissociation, depersonalisation
  • Loss of consciousness
  • Depression of heart rate and respiration (risk increases with increased dose or when combined with depressants)

Harm Reduction

  • Avoid driving at all costs.
  • Avoid walking or moving around in general if you are on a medium to hole dose.
  • Taking this on a non-empty substance could lead to nausea.

Interactions

Drug Combinations

Chemistry and Pharmacology

Examination of MXEMethoxetamine molecule showed that, similar to Ketamine, the 2 isomers have totally different effects with the (S) having potent NMDAN-methyl-D-aspartate receptor. NMDA antagonists are often dissociatives. activity (when the -OCH3 is deprotected to -OH, it gets stronger) while the (R) isomerEach of two or more compounds with the same formula but a different arrangement of atoms in the molecule and different properties. has SRISerotonin Reuptake Inhibitor effects and possibly a opioid metabolite.

MXEMethoxetamine is generally sold racemic.

Legal status

Methoxetamine is illegal in the US states Arizona[1], Florida[2], Indiana[3], Louisiana[4], Minnesota[5], North Dakota[6], Ohio[7] and Virginia[8]. It is also banned in Brazil, France, Germany, Japan, Russia and the UK[9].

Links

Wikipedia

Erowid

Drugs-Forum

/r/Drugs FAQ

References

  1. http://www.azleg.gov/DocumentsForBill.asp?Session_ID=112&Bill_Number=HB2453
  2. http://www.leg.state.fl.us/Statutes/index.cfm?App_mode=Display_Statute&URL=0800-0899/0893/0893.html
  3. http://www.in.gov/legislative/ic/2010/title35/ar31.5/ch2.html
  4. http://www.legis.la.gov/legis/ViewDocument.aspx?d=850979&n=HB10%20Act
  5. https://www.revisor.mn.gov/statutes/?id=152.02
  6. http://www.legis.nd.gov/cencode/t19c03-1.pdf?20140721032549
  7. http://www.legislature.state.oh.us/BillText130/130_HB_315_RH_N.html
  8. http://lis.virginia.gov/cgi-bin/legp604.exe?000+cod+54.1-3446
  9. http://www.legislation.gov.uk/uksi/2013/239/contents/made

Top Contributors